Skip to content
Med Rx.

Glecaprevir + Pibrentasvir + Venetoclax

Major 8 published sources

This interaction is documented in this data source.

Glecaprevir + Pibrentasvir
Checked as Glecaprevir + Pibrentasvir
Venetoclax
Checked as Venetoclax

2 documented mechanisms

This source documents more than one distinct mechanism for this pair. Each is shown with its own effect, advice and sources rather than merged into one.

  1. Mechanism 1: Absorption

    Major

    via Glecaprevir and Venetoclax

    What happens

    Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.

    What to do

    Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.

    5 sources

    1. "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
    2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
    3. Cerner Multum, Inc. "Australian Product Information." O 0
    4. "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
    5. "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.

  2. Mechanism 2: Absorption

    Major

    via Glecaprevir and Venetoclax

    What happens

    Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.

    What to do

    Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.

    3 sources

    1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
    2. Cerner Multum, Inc. "Australian Product Information." O 0
    3. "Product Information. Venclexta (venetoclax)." AbbVie US LLC (2016):

Keep checking